ENHERTU® (fam-trastuzumab deruxtecan-nxki) Patient Website
WEBWhat is ENHERTU? ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
Enhertu: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBJul 11, 2024 · Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 gene mutations. Includes Enhertu side effects, uses, package insert and more.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Trastuzumab deruxtecan - Wikipedia
WEBTrastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan).
Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer
WEBJul 5, 2022 · Enhertu extended survival in patients with metastatic HER2-low breast cancer longer than standard chemo, a clinical trial showed.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
WEBWhat is ENHERTU? ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy: - for metastatic disease, or.
Enhertu (fam-trastuzumab deruxtecan-nxki): Uses, Side Effects ... - WebMD
WEBJun 21, 2024 · Enhertu (fam-trastuzumab deruxtecan-nxki) is commonly used for treating different kinds of HER2 cancers in adults. HER2 is a protein that some cancers express and it allows the cancer cells to...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official HCP Site
WEBENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:
WEBENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
FDA approves new treatment option for patients with HER2 …
WEBFDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more...